Isamu Tachibana, M.D.

Isamu Tachibana M.D, is an Assistant Professor in the Department of Urology at UT Southwestern Medical Center. He specializes in urologic malignancies including bladder, kidney, prostate, adrenal, penile, and testicular cancer.

He grew up in Texas, graduating with honors from Rice University and UT Southwestern Medical School.  He went on to complete urology residency and urologic oncology fellowship at Indiana University School of Medicine where he received advanced training in complex oncologic procedures including locally advanced kidney cancer and various urinary diversions such as continent urinary reservoirs (Indiana Pouch) and neobladders. He has a particular interest in the treatment of testicular cancer.

Dr. Tachibana has published research in a variety of medical journal including Journal of Clinical Oncology, European Urology, Journal of Urology, and Urologic Oncology. He also serves as a reviewer for these journals. His interests outside of medicine include hiking, playing tennis, and spending time with family.

Medical School

UT Southwestern Medical Center School of Health Professions (2016)

Residency

Indiana University School of Medicine (2021), Urology

Fellowship

Indiana University School of Medicine (2023), Urologic Oncology

Featured Publications

Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?

Tachibana I, Alabd A, Tong Y, Piroozi A, Mahmoud M, Kern SQ, Masterson TA, Adra N, Foster RS, Hanna NH, Einhorn LH, Cary C, J Clin Oncol 2023 Aug 41 23 3930-3938

Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy.

Tachibana I, Alabd A, Whaley RD, McFadden J, Piroozi A, Hassoun R, Kern SQ, King J, Adra N, Rice KR, Foster RS, Einhorn LH, Cary C, Masterson TA, Urol Oncol 2023 Aug

Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?

Tachibana I, Kern SQ, Douglawi A, Tong Y, Mahmoud M, Masterson TA, Adra N, Foster RS, Einhorn LH, Cary C, J Clin Oncol 2022 Nov 40 32 3762-3769

Delaying Cancer Cases in Urology during COVID-19: Review of the Literature.

Tachibana I, Ferguson EL, Mahenthiran A, Natarajan JP, Masterson TA, Bahler CD, Sundaram CP, J Urol 2020 Nov 204 5 926-933

Long-Term Oncologic Outcomes after Primary Retroperitoneal Lymph Node Dissection: Minimizing the Need for Adjuvant Chemotherapy.

Douglawi A, Calaway A, Tachibana I, Panizzutti Barboza M, Speir R, Masterson T, Adra N, Foster R, Einhorn L, Cary C, J Urol 2020 Jul 204 1 96-103

Oncologic Outcomes Following Surgical Management of Clinical Stage II Sex Cord Stromal Tumors.

Calaway AC, Tachibana I, Masterson TA, Foster RS, Einhorn LH, Cary C, Urology 2019 May 127 74-79

• American Urologic Association Best Poster
  (2023)
• Alpha Omega Alpha
  (2016)

• American Urologic Association (2016)
• Society of Urologic Oncology (2023)